RNF31 and Patent ductus arteriosus: To next assess whether loss of Rnf31 also sensitizes human PDA to TNF-mediated cell death, we generated patient-derived and engineered human pancreatic cancer organoids (hPDA) with RNF31KO mutations and treated these organoids for four hours with TNF.